The Life Sciences team advised Oak Hill Bio in an exclusive license agreement with Roche to obtain global rights for rugonersen. Rugonersen is an ASO designed as a potential best-in-class treatment for individuals with Angelman syndrome, a rare, genetic neurodevelopmental condition for which there is no approved disease-modifying treatment. Oak Hill plans to initiate a Phase 3 study in early 2026.
Oak Hill Bio Ltd is a clinical-stage biotechnology company focused on acquiring and developing life-changing rare disease therapeutics. The company’s pipeline includes two programs in late-stage clinical development – potential treatments for Angelman syndrome and complications of extremely premature birth – as well as a preclinical program for diabetic macular edema. Oak Hill has operations in the United States and the United Kingdom.
The Goodwin team was led by Sarah Solomon and Zhenghui (Alan) Wang (Life Sciences Licensing), with invaluable support from Bill Collins, Sam Beavers and Michael Grainger (Corporate), Joshua Weinger (IP Litigation), Christopher Zhong and Yichen Xu (Life Sciences Licensing), Susan Lee (FDA Regulatory) and Gabe Maldoff (Data Privacy).
For more information on the deal, please read the press release.